Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Immuneering (NASDAQ:IMRX) from a sell rating to a hold rating in a research note issued to investors on Saturday.

IMRX has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. Chardan Capital reiterated a “buy” rating and set a $20.00 price objective on shares of Immuneering in a research note on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Price Performance

Shares of NASDAQ:IMRX opened at $5.62 on Friday. The business has a 50-day moving average of $5.20 and a two-hundred day moving average of $6.13. The firm has a market capitalization of $362.88 million, a PE ratio of -4.07 and a beta of 0.46. Immuneering has a 12 month low of $1.10 and a 12 month high of $10.08.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.13. As a group, research analysts anticipate that Immuneering will post -1.86 earnings per share for the current year.

Insider Activity

In related news, Director Thomas J. Schall bought 21,645 shares of the stock in a transaction dated Thursday, January 15th. The stock was acquired at an average price of $4.67 per share, for a total transaction of $101,082.15. Following the completion of the purchase, the director owned 74,530 shares in the company, valued at $348,055.10. This represents a 40.93% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Peter Feinberg bought 20,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the acquisition, the director owned 135,441 shares in the company, valued at approximately $589,168.35. This trade represents a 17.32% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 51,819 shares of company stock valued at $234,472 in the last ninety days. Company insiders own 22.90% of the company’s stock.

Institutional Trading of Immuneering

Large investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in shares of Immuneering during the first quarter worth $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in Immuneering during the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in Immuneering during the 3rd quarter valued at $35,000. Future Financial Wealth Managment LLC purchased a new stake in Immuneering during the 3rd quarter worth $35,000. Finally, Kingsview Wealth Management LLC purchased a new stake in Immuneering during the 2nd quarter worth $47,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.